Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012235 | 0.94 | HRH4 (0.45) | KMT2AHRH4MEN1HRH3HRH1 | |
| SCHEMBL13401443 | 0.87 | HRH4 (0.36) | KMT2AHRH4MEN1 | |
| SCHEMBL13401445 | 0.83 | FPR2 (0.41) | SYKKMT2AHRH4MEN1HRH3 | |
| SCHEMBL13410084 | 0.82 | SYK (0.31) | SYK | |
| SCHEMBL13401571 | 0.82 | HRH4 (0.36) | HRH4 | |
| Pibrozelesin SCHEMBL14499178 | 0.79 | P4HB (0.44) | SYKHRH4 | |
| SCHEMBL13401572 | 0.79 | HRH4 (0.34) | KMT2AHRH4 | |
| Pibrozelesin SCHEMBL29352513 | 0.79 | P4HB (0.44) | SYKHRH4 | |
| SCHEMBL7470059 | 0.78 | P4HB (0.37) | SYKHRH4 | |
| SCHEMBL12201083 | 0.78 | HRH4 (0.37) | KMT2AHRH4MEN1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | SYK 910/4885KMT2A 3304/4885HRH4 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.